focus -WSS

focus

author：Wikipedia 2025-09-06 03:17:37 - browse：484

Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT — Adobe

Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： State of the Union pitch: Bigger Medicare drug price negotiations

WSS

First over

Generate Biomedicines machine learning biotech raises $273M

Will the IRA bring competition to the biologics market?

New weight loss drugs vying to be the next Wegovy or Mounjaro

Families look for replacement for GSK asthma drug Flovent

Private equity could exacerbate cardiology's overuse problem, experts fear

entertainment

focus

hotspot

Affirmative action in medical school literally saved lives

Families look for replacement for GSK asthma drug Flovent

Virginia high school admissions case could be legal follow

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

What does generative AI mean for health care? We asked experts

Food makers to regulators: Ultra

BioMarin wins approval for gene therapy to treat hemophilia A

He's 19 months old and has one of the world’s rarest diseases

Virginia high school admissions case could be legal follow

Pig kidney works a record two months in donated body

hotspot

Florida health officials providing scant details on measles cases

Acelyrin, a rare IPO success, stumbles in its first big test

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

A new approach to psychiatric drug development

Food makers to regulators: Ultra

Lack of health data on LGBTQ+ people has serious consequences

hotspot

entertainment

hotspot

knowledge